S&P Futures
4,533.25 -42.50 (-0.93%) Dow Futures
34,559.00 -63.00 (-0.18%) Nasdaq Futures
15,687.50 -301.00 (-1.88%) Russell 2000 Futures
2,156.20 -49.00 (-2.22%) Crude Oil
66.22 -0.28 (-0.42%) Gold
1,782.10 +21.40 (+1.22%)
Jounce Therapeutics, Inc. (JNCE)
After hours:
Chart Events
Performance Outlook
| Previous Close | 7.61 |
| Open | 7.64 |
| Bid | 5.01 x 1400 |
| Ask | 7.24 x 800 |
| Day's Range | 7.11 - 7.64 |
| 52 Week Range | 5.03 - 14.84 |
| Volume | |
| Avg. Volume | 506,533 |
| Market Cap | 365.116M |
| Beta (5Y Monthly) | 1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.15 |
| Earnings Date | May 04, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.40 |
- Benzinga
Notable Jounce Therapeutics Insider Makes $15M Sale
Mark Levin, Insider at Jounce Therapeutics (NASDAQ:JNCE), made a large insider sell on November 12, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Friday showed that Levin sold 1,900,000 shares of Jounce Therapeutics at a price of $8.38. The total transaction amounted to $15,922,000. Following the transaction, Levin still owns 1,432,638 shares of the company, worth $12,678,846. Jounce Therapeutics shares are trading down 1.67% at
- GlobeNewswire
Jounce Therapeutics to Present at Upcoming Investor Conferences in November
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that company management will participate at the following upcoming investor conferences in November: 5th Annual Cowen IO Next Summit: Fireside chat on Monday, November 15, 2021 at 10:45 a.m. ET.33rd Annual Piper Sandler Healthcare Conference: Fireside chat availabl
- Motley Fool
Jounce Therapeutics, inc (JNCE) Q3 2021 Earnings Call Transcript
JNCE earnings call for the period ending September 30, 2021.
